These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15114071)

  • 1. Hard decisions about fundamental values.
    Laupacis A
    Healthc Pap; 2004; 4(3):60-6; discussion 68-72. PubMed ID: 15114071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taking our medicine: who should pay for what?
    Deber R
    Healthc Pap; 2004; 4(3):27-8; discussion 68-72. PubMed ID: 15114066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Romanow pharmacare: last-dollar first...first-dollar lost?
    Morgan SG; Willison DJ
    Healthc Pap; 2004; 4(3):10-20. PubMed ID: 15114064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stop the merry-go-round.
    Lexchin J
    Healthc Pap; 2004; 4(3):29-34; discussion 68-72. PubMed ID: 15114067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug policy: an oxymoron?
    Gray J
    Healthc Pap; 2002; 3(1):56-62; discussion 87-94. PubMed ID: 12811112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of economic evaluation in the pricing and reimbursement of medicines.
    Drummond M; Jönsson B; Rutten F
    Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health resource allocation. A made-in-Canada description.
    Noseworthy T
    J Leg Med; 2011 Jan; 32(1):11-26. PubMed ID: 21391053
    [No Abstract]   [Full Text] [Related]  

  • 11. Centralising drug review to improve coverage decisions: economic lessons from (and for) Canada.
    Morgan S; McMahon M; Mitton C
    Appl Health Econ Health Policy; 2006; 5(2):67-73. PubMed ID: 16872248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHARMAC measures savings elsewhere to the health sector.
    Metcalfe S; Dougherty S; Brougham M; Moodie P
    N Z Med J; 2003 Mar; 116(1170):U362. PubMed ID: 12658320
    [No Abstract]   [Full Text] [Related]  

  • 14. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug reimbursement in Finland-a case of explicit prioritizing in special categories.
    Vuorenkoski L; Toiviainen H; Hemminki E
    Health Policy; 2003 Nov; 66(2):169-77. PubMed ID: 14585516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Australian government's review of positron emission tomography: evidence-based policy decision-making in action.
    Lenzo NP
    Med J Aust; 2004 Nov; 181(9):516-7; author reply 517-8. PubMed ID: 15516203
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.
    Teerawattananon Y; Tritasavit N; Suchonwanich N; Kingkaew P
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):397-404. PubMed ID: 25444298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring access to high cost, genetically targeted drugs.
    Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
    Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National pharmacare: a dog's tale.
    Anis AH
    CMAJ; 2004 Sep; 171(6):565-6. PubMed ID: 15367455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.